|  |  |
| --- | --- |
| **Domain:** | Substance Use-related Co-morbidities and Health-related Outcomes |
| **Measure:** | Health Quality Index for Economic Evaluations |
| **Definition:** | Instrument used to measure respondent’s quality of life, given medical conditions or health problems. |
| **Purpose:** | The purpose of this measure is to construct a quality-adjusted life year index that can be used to assess the relative burden of living with any given medical condition, including substance abuse addiction and other chronic conditions. |
| **Essential PhenX Measures:** | Current AgeGender |
| **Related PhenX Measures:** |  |
| **Collections:** | Quality of LifeSubstance Use-related Co-morbidities and Health-related OutcomesSCD Neurology, Quality of Life, and Health Services Additional Relevant Measures |
| **Keywords:** | Adolescent health, Anxiety, Child health, Depression, Discomfort, Feelings, EQ-5D, EQ-5D-Y, EuroQol Group, Health status, HRQOL, Measurement, Mobility, Pain, Quality of life, Self-care, Usual activities, VAS, Visual analogue scale, SAA, Substance Use-related Co-morbidities and Health-related Outcomes |

|  |  |
| --- | --- |
| **Protocol Release Date:** | February 24, 2012 |
| **PhenX Protocol Name:** | Health Quality Index for Economic Evaluations - Adult |
| **Protocol Name from Source:** | The Expert Review Panel has not reviewed this measure yet. |
| **Description:** | The EQ-5D is a standardized instrument for use as a measure of health outcomes. The EQ-5D is applicable to a wide range of health conditions and treatments; it provides a simple descriptive profile and a single index value for health status.  |
| **Specific Instructions:** | *Note: Licensing fees are determined by the EuroQol Executive Office on the basis of the user information provided on the registration form. The amount is dependent on the type of study, funding source, sample size, and number of requested languages. You are not obligated to purchase by registering.* *See EQ-5D User Guide for instructions and scoring.*  |
| **Protocol:** | The EQ-5D self-reported questionnaire includes a descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions:* Mobility
* Self-Care
* Usual Activities
* Pain/Discomfort
* Anxiety/Depression

Each dimension has five levels:* No problems
* Slight problems
* Moderate problems
* Severe problems
* Extreme problems

For the descriptive system, the respondent is asked to indicate his or her health state by marking the most appropriate statement in each of the five dimensions. This decision results in a one-digit number expressing the level selected for that dimension. The digits for five dimensions can be combined in a five-digit number describing the respondent’s health state.The visual analogue scale records the respondent’s self-rated health on a 20 cm vertical, visual analogue scale with endpoints labeled "the best health you can imagine" and "the worst health you can imagine." This information can be used as a quantitative measure of health, as judged by the individual respondents. EQ-5D™ is a trademark of the EuroQol Group. |
| **Selection Rationale:** | The EQ-5D is used in clinical and economic evaluations of health care and also in population health surveys. The instrument has multinational and national usages. It is being applied in multinational trials by pharmaceutical companies. |
| **Source:** | EuroQol Group. (2005). EQ-5D. Rotterdam, Netherlands: Author.The EQ-5D can be obtained by contacting the following:EuroQol Group Executive OfficeMarten Meesweg 1073068 AV RotterdamNetherlandsTelephone: +31 884400190E-mail: userinformationservice@eurogol.org  |
| **Life Stage:** | Adult |
| **Language of source:** | English, Available in other languages |
| **Participant:** | Adults aged 18 years or older |
| **Personnel and Training Required:** | None |
| **Equipment Needs:** | None |
| **Standards:** |

|  |  |  |  |
| --- | --- | --- | --- |
| **Standard** | **Name** | **ID** | **Source** |
| Common Data Element (CDE) | Adult Health Quality Index Assessment Score | 3373530 | [CDE Browser](https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&FirstTimer=0&PageId=ElementDetailsGroup&publicId=3373530&version=1.0) |

 |
| **General references:** | Bridges, J. (2003). Stated preference methods in health care evaluation: An emerging methodological paradigm in health economics. *Applied Health Economics and Health Policy, 2*(4), 213-224. Brooks, R., Rabin, R., & de Charro, F. (Eds). (2003). *The measurement and valuation of health status using EQ-5D: A European perspective.* Dordrecht, Netherlands: Kluwer Academic. Devlin, N. J., Hansen, P., Kind, P., & Williams, A. (2003). Logical inconsistencies in survey respondents’ health state valuations—A methodological challenge for estimating social tariffs. *Health Economics, 12*(7), 529-544. Dolan, P. (1997). Modeling valuations for EuroQol health states. *Medical Care, 35*(11), 1095-1108. Dolan, P. (1999). Whose preferences count? *Medical Decision Making, 19*(4), 482-486. Greiner, W., Weijnen, T., Nieuwenhuizen, M., Oppe, S., Badia, X., Busschbach, J., Buxton, M., Dolan, P., Kind, P., Krabbe, P., Ohinmaa, A., Parkin, D., Roset, M., Sintonen, H., Tsuchiya, A., & de Charo, F. (2003). A single European currency for EQ-5D health states. Results from a six-country study. *European Journal of Health Economics, 4*(3), 222-231. Kind, P. (2003). Guidelines for value sets in economic and non-economic studies using EQ-5D. Chapter 4 In R. Brooks, R. Rabin, & F. de Charro (Eds.), *The measurement and valuation of health status using EQ-5D: A European perspective* (pp. 29-42). Dordrecht, Netherlands: Kluwer. Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. *Medical Care, 43*(3), 203-220. |
| **Mode of Administration:** | Self-administered questionnaire |
| **Derived Variables:** | None |
| **Requirements:** |

|  |  |
| --- | --- |
| **Requirement Category** | **Required** |
| Major equipment | No |
| Specialized training | No |
| Specialized requirements for biospecimen collection | No |
| Average time of greater than 15 minutes in an unaffected individual | No |

 |
| **Process and Review:** | The Expert Review Panel has not reviewed this measure yet. |